Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tegavivint - Apollomics/Iterion Therapeutics

Next Previous
Drug Profile

Tegavivint - Apollomics/Iterion Therapeutics

Alternative Names: APL-121; BC-2059; Tegatrabetan - Iterion therapeutics

Latest Information Update: 10 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BetaCat Pharmaceuticals
  • Developer Apollomics; Iterion Therapeutics; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center
  • Class Anthracenes; Antineoplastics; Hydroxylamines; Nitroso compounds; Piperidines; Small molecules; Sulfonamides
  • Mechanism of Action Beta catenin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibroma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibroma
  • Phase I/II Liver cancer; Solid tumours
  • Phase I B-cell lymphoma
  • Preclinical Acute myeloid leukaemia; Lymphoma; Non-small cell lung cancer; Osteosarcoma
  • No development reported Multiple myeloma

Most Recent Events

  • 25 Apr 2025 Efficacy and adverse events data from a phase-I/II trials in Liver cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top